Genetic variants predisposing to cardiovascular disease

Current Opinion in Lipidology

Volumn 17, Issue 2, 2006, Pages 139-151

  Visvikis Siest, Sophie ^a   Marteau, Jean Brice ^a  

^a INSERM   (France)

Author keywords

Cardiovascular disease; Environment; Genetic

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSINOGEN; APOLIPOPROTEIN A5; APOLIPOPROTEIN E; APOLIPOPROTEIN M; ARYLDIALKYLPHOSPHATASE 1; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN CONVERTING ENZYME; GENE PRODUCT; LIPOPROTEIN LIPASE; LYMPHOTOXIN; MONOCYTE ENHANCER FACTOR 2A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE IV; PROTEIN; PROTEIN ALOX5AP; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCUS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HYPERTENSION; METHODOLOGY; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; ENZYMES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MULTIFACTORIAL INHERITANCE; PHENOTYPE; VARIATION (GENETICS);

EID: 33645509725     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000217895.67444.de     Document Type: Review

References (130)

1. Fox CS, Polak JF, Chazaro I, et al. Genetic and environment contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke 2003; 34:397-401.
2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431:931-945.
3. Marteau JB, Zaiou M, Siest G, Visvikis-Siest S. Genetic determinants of blood pressure regulation. J Hypertension 2005; 23:2127-2143. The authors highlight the genetic basis of hypertension and discuss limitations to clinical applications of genotypic information in the diagnosis.
4. Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 1999; 30:841-850.
5. Kauma H, Paivansalo M, Savolainen MJ, et al. Association between angiotensin converting enzyme gene polymorphism and carotid atherosclerosis. J Hypertens 1996; 14:1183-1187.
6. Huang XH, Loimaala A, Nenonen A, et al. Relationship of angiotensin-converting enzyme gene polymorphism to carotid wall thickness in middle-aged men. J Mol Med 1999; 77:853-858.
7. Hung J, McQuillan BM, Nidorf M, et al. Angiotensin-converting enzyme gene polymorphism and carotid wall thickening in a community population. Arterioscler Thromb Vasc Biol 1999; 19:1969-1974.
8. Sayed-Tabatabaei FA, Schut AF, Hofman A, et al. A study of gene-environment interaction on the gene for angiotensin converting enzyme: a combined functional and population based approach. J Med Genet 2004; 41:99-103.
9. Sayed-Tabatabaei FA, Schut AF, Vasquez AA, et al. Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. J Med Genet 2005; 42:26-30.
10. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.
11. van Berlo JH, Pinto YM. Polymorphisms in the RAS and cardiac function. Int J Biochem Cell Biol 2003; 35:932-943.
12. Ye S, Dhillon S, Seear R, et al. Epistatic interaction between variations in the angiotensin I converting enzyme and angiotensin II type 1 receptor genes in relation to extent of coronary atherosclerosis. Heart 2003; 89:1195-1199.
13. Fukazawa R, Sonobe T, Hamamoto K, et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res 2004; 56:597-601.
14. Varda NM, Peterlin B, Bradac SU, Gregoric A. Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. Acta Paediatr 2005; 94:33-37.
15. Fauci A, Braunwald E, Isselbacher K, et al. editors. Harrison's principles of internal medicine. 14th ed. New York McGraw-Hill; 1998.
16. Kim HS, Krege JH, Kluckman KD, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A 1995; 92:2735-2739.
17. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
18. Winkelmann BR, Russ AP, Nauck M, et al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999; 137:698-705.
19. Sethi AA, Nordestgaard BG, Gronholdt ML, et al. Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 2003; 41:1202-1211.
20. Sethi AA, Tybjaerg-Hansen A, Gronholdt ML, et al. Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease: six case-control studies from the Copenhagen City Heart Study. Ann Intern Med 2001; 134:941-954.
21. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23:1269-1275.
22. Chapman CM, Palmer LJ, McQuillan BM, et al. Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population. Atherosclerosis 2001; 159:209-217.
23. Sarzani R, Dessi-Fulgheri P, Mazzara D, et al. Cardiovascular phenotype of young adults and angiotensinogen alleles. J Hypertens 2001; 19:2171-2178.
24. Bozec E, Fassot C, Tropeano AI, et al. Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clin Sci (Lond) 2003; 105:637-644.
25. Lanz JR, Pereira AC, Lemos PA, et al. Angiotensinogen M235T polymorphism is associated with coronary artery disease severity. Clin Chim Acta 2005; 362:176-181.
26. Renner W, Nauck M, Winkelmann BR, et al. Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. J Mol Med 2005; 83:235-239.
27. Pallaud C, Sass C, Zannad F, et al. APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). Clin Genet 2001; 59:316-324.
28. McQuillan BM, Beilby JP, Nidorf M, et al. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) Circulation 1999; 99:2383-2388.
29. Inamoto N, Katsuya T, Kokubo Y, et al. Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 2003; 34:1628-1633.
30. Li Z, Sun L, Zhang H, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke 2003; 34:2085-2090.
31. Jiang S, Hsu YH, Xu X, et al. The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res 2004; 113:361-369.
32. Spotila LD, Jacques PF, Berger PB, et al. Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. Am J Epidemiol 2003; 158:871-877.
33. Steinberg D, Parthasarathy TE, Carew TE, et al. Beyond cholesterol: modification of low density lipoprotein that increases its atherogenicity. N Engl J Med 1989; 320:915-924.
34. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism MetLeu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99:62-66.
35. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20:516-521.
36. Robertson KS, Hawe E, Miller GJ, et al. Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta 2003; 1639:203-212.
37. Wheeler JG, Keavney BD, Watkins H, et al. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363:689-695. The most important metaanalysis of PON polymorphisms.
38. Durrington PN, Mackness B, Mackness MI. Paraoxonase polymorphisms and coronary heart disease. Lancet 2004; 364:579-580.
39. Jarvik GP, Jampsa R, Richter RJ, et al. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003; 13:291-295.
40. Ye S, Dunleavey L, Bannister W, et al. Independent effects of the -219 G>T and epsilon 2/epsilon 3/epsilon 4 polymorphisms in the apolipoprotein E gene on coronary artery disease: the Southampton Atherosclerosis Study. Eur J Hum Genet 2003; 11:437-443.
41. Lambert JC, Brousseau T, Defosse V, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations: the ECTIM study. Hum Mol Genet 2000; 9:57-61.
42. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 1999; 53:1308-1311.
43. Pezzini A, Grassi M, Del Zotto E, et al. Synergistic effect of apolipoprotein E polymorphisms and cigarette smoking on risk of ischemic stroke in young adults. Stroke 2004; 35:438-442.
44. Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology 2004; 62:1196-1198.
45. Fernandez-Miranda C, Aranda JL, Martin MA, et al. Apolipoprotein E polymorphism and carotid atherosclerosis in patients with coronary disease. Int J Cardiol 2004; 94:209-212.
46. Elosua R, Ordovas JM, Cupples LA, et al. Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res 2004; 45:1868-1875. This paper illustrates the importance of sex stratification and the role of diabetes in the APOE-atherosclerosis interaction. The results were confirmed by meta-analysis.
47. Schut AF, Sayed-Tabatabaei FA, Witteman JC, et al. Smoking-dependent effects of the angiotensin-converting enzyme gene insertion/deletion polymorphism on blood pressure. J Hypertens 2004; 22:313-319.
48. Wu SJ, Chiang FT, Jiang JR, et al. The G-217A variant of the angiotensinogen gene affects basal transcription and is associated with hypertension in a Taiwanese population. J Hypertens 2003; 21:2061-2067.
49. Wu SJ, Chiang FT, Chen WJ, et al. Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: single locus genotype vs. haplotype analysis. Physiol Genomics 2004; 17:79-86.
50. Jones A, Dhamrait SS, Payne JR, et al. Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. Hypertension 2003; 42:500-506.
51. Lai CQ, Tai ES, Tan CE, et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003; 44:2365-2373.
52. Hubacek JA, Skodova Z, Adamkova V, et al. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction. Clin Genet 2004; 65:126-130.
53. Liu H, Zhang S, Lin J, et al. Association between DNA variant sites in the apolipoprotein A5 gene and coronary heart disease in Chinese. Metabolism 2005; 54:568-572.
54. Szalai C, Keszei M, Duba J, et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 2004; 173:109-114.
55. Austin MA, Talmud PJ, Farin FM, et al. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans. Biochim Biophys Acta 2004; 1688:1-9.
56. Kao JT, Wen HC, Chien KL, et al. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003; 12:2533-2539.
57. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233-239. A well designed study including linkage analysis, microsatellite association study, LD mapping, haplotype association and screening for SNPs in ALOX5AP, which clearly defines this molecule as a new candidate gene for CAD.
58. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004; 41:758-762.
59. Paradossi U, Ciofini E, Clerico A, et al. Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298→Asp and T-786→C polymorphisms. Stroke 2004; 35:1305-1309.
60. Shearman AM, Karasik D, Gruenthal KM, et al. Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 2004; 19:773-781.
61. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 2004; 291:2969-2977.
62. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32:650-654.
63. Bhagavatula MR, Fan C, Shen GQ, et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Genet 2004; 13:3181-3188. Two percent of the CAD/MI population may carry mutations in the MEF2A gene.
64. Gonzalez P, Garcia-Castro M, Reguero JR, et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet 2005; 15 June [E-pub ahead of print].
65. Nojiri T, Morita H, Imai Y, et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol 2003; 92:181-186.
66. Bevan S, Porteous L, Sitzer M, Markus HS. Phosphodiesterase 4D gene, ischemic stroke, and asymptomatic carotid atherosclerosis. Stroke 2005; 36:949-953.
67. Oliveira SA, Mansur AP, Ribeiro CC, et al. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004; 94:73-77.
68. Masud S, Ye S, SAS Group. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003; 40:773-780.
69. Cakir B, Heiss G, Pankow JS, et al. Association of the Lewis genotype with cardiovascular risk factors and subclinical carotid atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. J Intern Med 2004; 255:40-51.
70. Bianchi G, Manunta P. Adducin, renal intermediate phenotypes, and hypertension. Hypertension 2004; 44:394-395.
71. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, et al. Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke 2003; 34:1634-1639.
72. Ordovas JM. The quest for cardiovascular health in the genomic era: nutrigenetics and plasma lipoproteins. Proc Nutr Soc 2004; 63:145-152.
73. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003; 44:1080-1093.
74. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004; 109:1359-1365.
75. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3:292-299.
76. Lawlor DA, Day IN, Gaunt TR, et al. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet 2004; 5:17.
77. Castaman G, Faioni EM, Tosetto A, Bernardi F. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003; 88:1182-1189.
78. Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003; 302:1578-1581.
79. Mathias G. Microarray applications: emerging technologies and perspectives. Drug Discov Today 2004; 9:915-917.
80. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 2003; 100:1238-1243.
81. Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76:505-509.
82. Lohmussaar E, Gschwendtner A, Mueller JC, et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 2005; 36:731-736.
83. Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005; 293:2245-2256.
84. Yamada A, Ichihara S, Murase Y. Lack of association of polymorphisms of the lymphotoxin alpha gene with myocardial infarction in Japanese. J Mol Med 2004; 82:477-483.
85. Koch W, Tiroch K, von Beckerath N, et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 2003; 24:161-171.
86. PROCARDIS Consortium. A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease. Eur J Hum Genet 2004; 12:770-774.
87. Laxton R, Pearce E, Kyriakou T, Ye S. Association of the lymphotoxin-alpha gene Thr26Asn polymorphism with severity of coronary atherosclerosis. Genes Immun 2005; 6:539-541.
88. Nakayama T, Soma M, Sato N, et al. An association study in essential hypertension using functional polymorphisms in lymphotoxin-alpha gene. Am J Hypertens 2004; 17:1045-1049.
89. Ozaki K, Inoue K, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004; 429:72-75. LGALS2 is significantly associated with susceptibility to MI. These findings suggest a link between the LTA cascade and the pathogenesis of MI.
90. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999; 274:31286-31290.
91. Xu N, Zhang XY, Dong X, et al. Effects of platelet-activating factor, tumor necrosis factor, and interleukin-1 alpha on the expression of apolipoprotein M in HepG2 cells. Biochem Biophys Res Commun 2002; 292:944-950.
92. Richter S, Shih DQ, Pearson ER, et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1 alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52:2989-2995.
93. Xu N, Hurtig M, Zhang XY, et al. Transforming growth factor-beta downregulates apolipoprotein M in HepG2 cells. Biochim Biophys Acta 2004; 1683:33-37.
94. Xu N, Nilsson-Ehle P, Hurtig M, Ahren B. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. Biochem Biophys Res Commun 2004; 321:916-921. Leptin is physiologically regulating apoM synthesis in vivo.
95. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005; 11:418-422. ApoM could inhibit formation of atherosclerotic lesions in vivo.
96. Kabbara A, Payet N, Cottel D, et al. Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population. Neurosci Lett 2004; 363:139-143.
97. Gretarsdottir S, Sveinbjornsdottir S, Jonsson HH, et al. Localization of a susceptibility gene for common forms of stroke to 5q12. Am J Hum Genet 2002; 70:593-603.
98. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003; 353:131-138.
99. Chen Y, Li Y, Zhang P, et al. Dimethylarginine dimethlyaminohydrolase and endothelial dysfunction in the failing heart. Am J Physiol Heart Circ Physiol 2005; 289:H2212-H2219.
100. Jones LC, Tran CT, Leiper JM, et al. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003; 310:836-843.
101. Funke-Kaiser H, Thomas A, Bremer J, et al. Regulation of the major isoform of human endothelin-converting enzyme-1 by a strong housekeeping promoter modulated by polymorphic microsatellites. J Hypertens 2003; 21:2111-2124.
102. Funke-Kaiser H, Reichenberger F, Kopke K, et al. Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. Hum Mol Genet 2003; 12:423-433.
103. Funalot B, Courbon D, Brousseau T, et al. Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: the EVA study. J Hypertens 2004; 22:739-743.
104. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 1995; 270:29794-29798.
105. Archacki S, Wang Q. Expression profiling of cardiovascular disease. Hum Genomics 2004; 1:355-370.
106. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999; 142:105-112.
107. Pauciullo P, Giannino A, De Michele M, et al. Increased carotid artery intima-media thickness is associated with a novel mutation of low-density lipoprotein receptor independently of major cardiovascular risk factors. Metabolism 2003; 52:1433-1438.
108. Alevizaki M, Cimponeriu AT, Garofallaki M, et al. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men. Clin Endocrinol 2003; 59:749-755.
109. Poirier O, Nicaud V, Gariepy J, et al. Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness: the ECTIM, AXA, EVA and GENIC studies. Eur J Hum Genet 2004; 12:213-219.
110. Brandstrom H, Stiger F, Kahan T, et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) Blood Press 2004; 13:152-157.
111. Archacki SR, Angheloiu G, Tian XL, et al. Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiol Genomics 2003; 15:65-74.
112. Juo SH, Lin HF, Rundek T, et al. Genetic and environmental contributions to carotid intima-media thickness and obesity phenotypes in the Northern Manhattan Family Study. Stroke 2004; 35:2243-2247.
113. McCarthy JJ, Parker A, Salem R, et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004; 41:334-341.
114. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol 2003; 42:1429-1437.
115. Delerive P, Fruchart C, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169:453-459.
116. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108:2805-2811.
117. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2004; 288:H1037-H1043.
118. Peng DQ, Zhao SP, Nie S, Li J. Gene-gene interaction of PPARgamma and ApoE affects coronary heart disease risk. Int J Cardiol 2003; 92:257-263.
119. Marteau JB, Sass C, Pfister M, et al. The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. J Hypertens 2004; 22:305-311.
120. Martin S, Nicaud V, Humphries SE, et al. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Biochim Biophys Acta 2003; 1637:217-225.
121. Pennacchio LA, Olivier M, Hubacek JA, et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Molec Genet 2002; 11:3031-3038.
122. Evans D, Buchwald A, Beil FU. The single nucleotide polymorphism -1131T>C in the apolipoprotein A5 (APOA5) gene is associated with elevated triglycerides in patients with hyperlipidemia. J Mol Med 2003; 81:645-654.
123. Xin X, Srinivasan SR, Chen W, et al. Interaction effect of Serine447Stop variant of the lipoprotein lipase gene and C-514T variant of the hepatic lipase gene on serum triglyceride levels in young adults: the Bogalusa Heart Study. Metabolism 2003; 52:1337-1342.
124. Hubacek JA, Horinek A, Skodova Z, et al. Hypertriglyceridemia: interaction between APOE and APOAV variants. Clin Chem 2005; 51:1311-1313.
125. Lee J, Tan CS, Chia KS, et al. The lipoprotein lipase S447X polymorphism and plasma lipids: interactions with APOE polymorphisms, smoking, and alcohol consumption. J Lipid Res 2004; 45:1132-1139.
126. Skogsberg J, McMahon AD, Karpe F, et al. West of Scotland Coronary Prevention Study. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 2003; 254:597-604.
127. Arias-Vasquez A, Sayed-Tabatabaei FA, Schut AF, et al. Angiotensin converting enzyme gene, smoking and mortality in a population-based study. Eur J Clin Invest 2005; 35:444-449.
128. Hokanson JE, Kamboh MI, Scarboro S, et al. Effects of the hepatic lipase gene and physical activity on coronary heart disease risk. Am J Epidemiol 2003; 158:836-843.
129. Goodarzi MO, Guo X, Taylor KD, et al. Lipoprotein lipase is a gene for insulin resistance in Mexican Americans. Diabetes 2004; 53:214-220.
130. Jerrard-Dunne P, Sitzer M, Risley P, et al. Inflammatory gene load is associated with enhanced inflammation and early carotid atherosclerosis in smokers. Stroke 2004; 35:2438-2443.